Colchicine

Colchicine is a medication used to treat gout^[2][3] and Behçet's disease.^[4] In gout, it is less preferred than NSAIDs or steroids.^[2] Other uses for colchicine include the management of pericarditis and familial Mediterranean fever.^[2][5] Colchicine is taken by mouth.^[2]

Colchicine

Clinical data
Pronunciation	/ˈkɒltʃɪsiːn/ KOL-chiss-een
Trade names	Colcrys, Mitigare, others
AHFS/Drugs.com	Monograph
MedlinePlus	a682711
License data	US DailyMed: Colchicine
Pregnancy category	AU: D
Routes of administration	By mouth
ATC code	M04AC01 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) CA: ℞-only UK: POM (Prescription only) US: ℞-only^[1]
Pharmacokinetic data
Bioavailability	45%
Protein binding	35-44%
Metabolism	Metabolism, partly by CYP3A4
Elimination half-life	26.6-31.2 hours
Excretion	Feces (65%)
Identifiers
IUPAC name N-[(7S)-1,2,3,10-Tetramethoxy-9-oxo-5,6,7,9-tetrahydrobenzo[a]heptalen-7-yl]acetamide
CAS Number	64-86-8^Y
PubChem CID	6167
IUPHAR/BPS	2367
DrugBank	DB01394^Y
ChemSpider	5933^Y
UNII	SML2Y3J35T
KEGG	D00570^Y
ChEBI	CHEBI:27882^Y
ChEMBL	ChEMBL107^Y
CompTox Dashboard (EPA)	DTXSID5024845 DTXSID20274387, DTXSID5024845
ECHA InfoCard	100.000.544
Chemical and physical data
Formula	C22H25NO6
Molar mass	399.443 g·mol^−1
3D model (JSmol)	Interactive image
SMILES CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC
InChI InChI=1S/C22H25NO6/c1-12(24)23-16-8-6-13-10-19(27-3)21(28-4)22(29-5)20(13)14-7-9-18(26-2)17(25)11-15(14)16/h7,9-11,16H,6,8H2,1-5H3,(H,23,24)/t16-/m0/s1^Y Key:IAKHMKGGTNLKSZ-INIZCTEOSA-N^Y
(verify)

Colchicine has a narrow therapeutic index, so overdosing is a significant risk. Common side effects of colchicine include gastrointestinal upset, particularly at high doses.^[6] Severe side effects may include pancytopenia (low blood cell counts) and rhabdomyolysis, and the medication can be deadly in overdose.^[2] Whether colchicine is safe for use during pregnancy is unclear, but its use during breastfeeding appears to be safe.^[2][7] Colchicine works by decreasing inflammation via multiple mechanisms.^[8]

Colchicine, in the form of the autumn crocus (Colchicum autumnale), has been used as early as 1500 BC to treat joint swelling.^[9] It was approved for medical use in the United States in 1961.^[1] It is available as a generic medication.^[7] In 2020, it was the 241st most commonly prescribed medication in the United States, with more than 1 million prescriptions.^[10][11]

Colchicine is widely used in plant breeding for inducing polyploidy, where the number of chromosomes in plant cells are doubled. This frequently results in larger, hardier, faster-growing, and in general more desirable plants than the normally diploid parents.^[12]

Medical uses

Gout

Colchicine is an alternative for those unable to tolerate NSAIDs when treating gout.^{[13][14][15][16]} Low doses appear to be well tolerated and may reduce gout symptoms and pain (1.2 mg in one hour, followed by 0.6 mg an hour later).^[17] This low dose may have a similar effectiveness to NSAIDS.^[17] At high doses, side effects (primarily diarrhea, nausea, or vomiting) limit its use, however may be effective against pain.^[17] In addition, there is preliminary evidence that daily colchicine (0.6 mg twice daily) may be effective as a long-term prophylaxis when used with allopurinol to reduce the risk of increased uric acid levels and acute gout flares,^[3] although adverse gastrointestinal effects may occur.^[18]

For treating gout symptoms, colchicine is used orally with or without food, as symptoms first appear.^[19] Subsequent doses may be needed if symptoms worsen.^[19] A 2021 updated Cochrane review found that low-dose colchicine had benefits similar to NSAIDs.^[20]

Prevention of myocardial infarction

In June 2023, the U.S. FDA approved a low-dose colchicine regimen for the prevention of heart attacks in adult patients with multiple risk factors for cardiovascular disease. As an anti-inflammatory drug, a dose of 0.5mg/d reduces the rates of cardiovascular events by 25% to 30% in patients with coronary atherosclerosis. The drug is most effective in combination therapy with lipid-lowering and other anti-inflammatory medications.^[21]

Other conditions

Colchicine is also used as an anti-inflammatory agent for long-term treatment of Behçet's disease.^[22] It appears to have limited effect in relapsing polychondritis, as it may only be useful for the treatment of chondritis and mild skin symptoms.^[23] It is a component of therapy for several other conditions, including pericarditis, pulmonary fibrosis, biliary cirrhosis, various vasculitides, pseudogout, spondyloarthropathy, calcinosis, scleroderma, and amyloidosis.^[22][24][25] Research regarding the efficacy of colchicine in many of these diseases has not been performed.^[25] It is also used in the treatment of familial Mediterranean fever,^[22] in which it reduces attacks and the long-term risk of amyloidosis.^[26]

Colchicine is effective for prevention of atrial fibrillation after cardiac surgery.^[27] Potential applications for the anti-inflammatory effect of colchicine have been studied with regard to atherosclerosis and chronic coronary disease (e.g., stable ischemic heart disease).^[28] In people with recent myocardial infarction (recent heart attack), it has been found to reduce risk of future cardiovascular events. Its clinical use may grow to include this indication.^[29][30]

Contraindications

Long-term (prophylactic) regimens of oral colchicine are absolutely contraindicated in people with advanced kidney failure (including those on dialysis).^[19] About 10–20% of a colchicine dose is excreted unchanged by the kidneys; it is not removed by hemodialysis. Cumulative toxicity is a high probability in this clinical setting, and a severe neuromyopathy may result. The presentation includes a progressive onset of proximal weakness, elevated creatine kinase, and sensorimotor polyneuropathy. Colchicine toxicity can be potentiated by the concomitant use of cholesterol-lowering drugs.^[19]

Adverse effects

Deaths – both accidental and intentional – have resulted from overdose of colchicine.^[19] Typical side effects of moderate doses may include gastrointestinal upset, diarrhea, and neutropenia.^[14] High doses can also damage bone marrow, lead to anemia, and cause hair loss. All of these side effects can result from inhibition of mitosis,^[31] which may include neuromuscular toxicity and rhabdomyolysis.^[19]

Toxicity

According to one review, colchicine poisoning by overdose (range of acute doses of 7 to 26 mg) begins with a gastrointestinal phase occurring 10–24 hours after ingestion, followed by multiple organ dysfunction occurring 24 hours to 7 days after ingestion, after which the affected person either declines into multiple organ failure or recovers over several weeks.^[32]

Colchicine can be toxic when ingested, inhaled, or absorbed in the eyes.^[14] It can cause a temporary clouding of the cornea and be absorbed into the body, causing systemic toxicity. Symptoms of colchicine overdose start 2 to 24 hours after the toxic dose has been ingested, and include burning in the mouth and throat, fever, vomiting, diarrhea, and abdominal pain.^[19] This can cause hypovolemic shock due to extreme vascular damage and fluid loss through the gastrointestinal tract, which can be fatal.^[32][33]

If the affected persons survive the gastrointestinal phase of toxicity, they may experience multiple organ failure and critical illness. This includes kidney damage, which causes low urine output and bloody urine; low white blood cell counts that can last for several days; anemia; muscular weakness; liver failure; hepatomegaly; bone marrow suppression; thrombocytopenia; and ascending paralysis leading to potentially fatal respiratory failure. Neurologic symptoms are also evident, including seizures, confusion, and delirium; children may experience hallucinations. Recovery may begin within six to eight days and begins with rebound leukocytosis and alopecia as organ functions return to normal.^[31][32]

Long-term exposure to colchicine can lead to toxicity, particularly of the bone marrow, kidney, and nerves. Effects of long-term colchicine toxicity include agranulocytosis, thrombocytopenia, low white blood cell counts, aplastic anemia, alopecia, rash, purpura, vesicular dermatitis, kidney damage, anuria, peripheral neuropathy, and myopathy.^[31]

No specific antidote for colchicine is known, but supportive care is used in cases of overdose. In the immediate period after an overdose, monitoring for gastrointestinal symptoms, cardiac dysrhythmias, and respiratory depression is appropriate,^[31] and may require gastrointestinal decontamination with activated charcoal or gastric lavage.^[32][33]

Because colchicine is so toxic, chemists are continuing to try to synthesize derivatives of the molecule that decrease the toxicity. The most important aspect of these derivatives is that they keep the tropolone ring (the ring with the methoxy group and the carbonyl) intact to retain the mechanistic properties of the molecule.^[34]

Mechanism of toxicity

With overdoses, colchicine becomes toxic as an extension of its cellular mechanism of action via binding to tubulin.^[32] Cells so affected undergo impaired protein assembly with reduced endocytosis, exocytosis, cellular motility, and interrupted function of heart cells, culminating in multiple organ failure.^[8][32]

Epidemiology

In the United States, several hundred cases of colchicine toxicity are reported annually, about 10% of which end with serious morbidity or mortality. Many of these cases are intentional overdoses, but others were accidental; for example, if the drug were not dosed appropriately for kidney function. Most cases of colchicine toxicity occur in adults. Many of these adverse events resulted from the use of intravenous colchicine.^[25]

Drug interactions

Colchicine interacts with the P-glycoprotein transporter, and the CYP3A4 enzyme involved in drug and toxin metabolism.^[19][32] Fatal drug interactions have occurred when colchicine was taken with other drugs that inhibit P-glycoprotein and CYP3A4, such as erythromycin or clarithromycin.^[19]

People taking macrolide antibiotics, ketoconazole, or cyclosporine, or those who have liver or kidney disease, should not take colchicine, as these drugs and conditions may interfere with colchicine metabolism and raise its blood levels, potentially increasing its toxicity abruptly.^[19][32] Symptoms of toxicity include gastrointestinal upset, fever, muscle pain, low blood cell counts, and organ failure.^[14][19] People with HIV/AIDS taking atazanavir, darunavir, fosamprenavir, indinavir, lopinavir, nelfinavir, ritonavir, or saquinavir may experience colchicine toxicity.^[19] Grapefruit juice and statins can also increase colchicine concentrations.^[19][35]

Pharmacology

Mechanism of action

In gout, inflammation in joints results from the precipitation of uric acid as needle-like crystals of monosodium urate in and around synovial fluid and soft tissues of joints.^[8] These crystal deposits cause inflammatory arthritis, which is initiated and sustained by mechanisms involving various proinflammatory mediators, such as cytokines.^[8] Colchicine accumulates in white blood cells and affects them in a variety of ways - decreasing motility, mobilization (especially chemotaxis), and adhesion.^[25]

Under preliminary research are various mechanisms by which colchicine may interfere with gout inflammation:

• Inhibits microtubule polymerization by binding to its constitutive protein, tubulin^[8]
• As availability of tubulin is essential to mitosis, colchicine may inhibit mitosis^[8]
• Inhibits activation and migration of neutrophils to sites of inflammation^[19]
• Interferes with the inflammasome complex found in neutrophils and monocytes that mediate interleukin-1β activation, a component of inflammation^[19]
• Inhibits superoxide anion production in response to urate crystals^[8]
• Interrupts mast cell and lysosome degranulation^[8][25]
• Inhibits release of glycoproteins that promote chemotaxis from synovial cells and neutrophils^[25]

Generally, colchicine appears to inhibit multiple proinflammatory mechanisms, while enabling increased levels of anti-inflammatory mediators.^[8] Apart from inhibiting mitosis, colchicine inhibits neutrophil motility and activity, leading to a net anti-inflammatory effect, which has efficacy for inhibiting or preventing gout inflammation.^[8][19]

Pharmacokinetics

Colchicine appears to be a peripherally selective drug with limited brain uptake due to binding to P-glycoprotein.^[36][37][38]

History

The plant source of colchicine, the autumn crocus (Colchicum autumnale), was described for treatment of rheumatism and swelling in the Ebers Papyrus (circa 1500 BC), an Egyptian medical text.^[39] It is a toxic alkaloid and secondary metabolite.^[14][40][19] Colchicum extract was first described as a treatment for gout in De Materia Medica by Pedanius Dioscorides, in the first century AD. Use of the bulb-like corms of Colchicum to treat gout probably dates to around 550 AD, as the "hermodactyl" recommended by Alexander of Tralles. Colchicum corms were used by the Persian physician Avicenna, and were recommended by Ambroise Paré in the 16th century, and appeared in the London Pharmacopoeia of 1618.^[41][25] Colchicum use waned over time, likely due to the severe gastrointestinal side effects preparations caused. In 1763, Colchicum was recorded as a remedy for dropsy (now called edema) among other illnesses.^[25] Colchicum plants were brought to North America by Benjamin Franklin, who had gout himself and had written humorous doggerel about the disease during his stint as United States Ambassador to France.^[42]

Colchicine was first isolated in 1820 by French chemists P. S. Pelletier and J. B. Caventou.^[43] In 1833, P. L. Geiger purified an active ingredient, which he named colchicine.^[44] It quickly became a popular remedy for gout.^[25] The determination of colchicine's structure required decades, although in 1945, Michael Dewar made an important contribution when he suggested that, among the molecule's three rings, two were seven-member rings.^[45] Its pain-relieving and anti-inflammatory effects for gout were linked to its ability to bind with tubulin.

The full synthesis of colchicine was achieved by the Swiss organic chemist Albert Eschenmoser in 1959.^[46]

United States Unapproved Drugs Initiative

An unintended consequence of the 2006 U.S. Food and Drug Administration (FDA) safety program called the Unapproved Drugs Initiative—through which the FDA sought more rigorous testing of efficacy and safety of colchicine and other unapproved drugs^[47]—was a price increase of 2000 percent ^[48] for "a gout remedy so old that the ancient Greeks knew about its effects".^[48] Under Unapproved Drugs Initiative small companies such as URL Pharma, a Philadelphia drugmaker, were rewarded with licenses for testing of medicines like colchicine. In 2009, the FDA reviewed a New Drug Application for colchicine submitted by URL Pharma. URL Pharma did the testing, gained FDA formal approval, and was granted rights over colchicine. With this monopoly pricing power, the price of colchicine increased.

In 2012, Asia's biggest drugmaker, Takeda Pharmaceutical Co., acquired URL Pharma for $800 million including the rights to colchicine (brand name Colcrys) earning $1.2 billion in revenue by raising the price even more.^[48]

Oral colchicine had been used for many years as an unapproved drug with no FDA-approved prescribing information, dosage recommendations, or drug interaction warnings.^[49] On 30 July 2009, the FDA approved colchicine as a monotherapy for the treatment of three different indications (familial Mediterranean fever, acute gout flares, and for the prophylaxis of gout flares^[49]), and gave URL Pharma a three-year marketing exclusivity agreement^[50] in exchange for URL Pharma doing 17 new studies and investing $100 million into the product, of which $45 million went to the FDA for the application fee. URL Pharma raised the price from $0.09 per tablet to $4.85, and the FDA removed the older unapproved colchicine from the market in October 2010, both in oral and intravenous forms, but allowed pharmacies to buy up the older unapproved colchicine.^[51] Colchicine in combination with probenecid has been FDA-approved before 1982.^[50]

On 29 July 2009, colchicine won FDA approval in the United States as a stand-alone drug for the treatment of acute flares of gout and familial Mediterranean fever.^[52][53] It had previously been approved as an ingredient in an FDA-approved combination product for gout. The approval was based on a study in which two doses (1.2 mg and 0.6 mg) an hour apart were as effective as higher doses in combating the acute flare of gout.^[54]

Marketing exclusivity in the United States

As a drug antedating the FDA, colchicine was sold in the United States for many years without having been reviewed by the FDA for safety and efficacy. The FDA reviewed approved colchicine for gout flares, awarding Colcrys a three-year term of market exclusivity, prohibiting generic sales, and increasing the price of the drug from $0.09 to $4.85 per tablet.^[55][56][57]

Numerous consensus guidelines, and previous randomized controlled trials, had concluded that colchicine is effective for acute flares of gouty arthritis. However, as of 2006, the drug was not formally approved by the FDA, owing to the lack of a conclusive randomized control trial. Through the Unapproved Drugs Initiative, the FDA sought more rigorous testing of the efficacy and safety of colchicine and other unapproved drugs.^[47] In exchange for paying for the costly testing, the FDA gave URL Pharma three years of market exclusivity for its Colcrys brand,^[58] under the Hatch-Waxman Act, based in part on URL-funded research in 2007, including pharmacokinetic studies and a randomized control trial with 185 patients with acute gout.

In April 2010, an editorial in the New England Journal of Medicine said that the rewards of this legislation are not calibrated to the quality or value of the information produced, that no evidence of meaningful improvement to public health was seen, and that it would be less expensive for the FDA, the National Institutes of Health, or large insurers to pay for trials themselves. Furthermore, the cost burden of this subsidy falls primarily on patients or their insurers.^[59] In September 2010, the FDA ordered a halt to marketing unapproved single-ingredient oral colchicine.^[60]

Colchicine patents expire on 10 February 2029.^[61]

Orphan drug

URL Pharma also received seven years of market exclusivity for Colcrys in the treatment of familial Mediterranean fever, under the Orphan Drug Law. URL Pharma then raised the price per tablet from $0.09 to $4.85 and sued to remove other versions from the market, increasing annual costs for the drug to U.S. state Medicaid programs from $1 million to $50 million. Medicare also paid significantly higher costs, making this a direct money-loser for the government. (In a similar case, thalidomide was approved in 1998 as an orphan drug for leprosy and in 2006 for multiple myeloma.)^[59]

Sources and uses

Physical properties

Colchicine has a melting point of 142-150 °C. It has a molecular weight of 399.4 grams per mole.^[62]

Structure

Colchicine has one stereocenter located at carbon 7. The natural configuration of this stereocenter is S. The molecule also contains one chiral axis - the single bond between rings A and C. The natural configuration of this axis is aS. Although colchicine has four stereoisomers, the only one found in nature is the aS,7s configuration.^[63]

Light sensitivity

Colchicine is a light-sensitive compound, so needs to be stored in a dark bottle. Upon exposure to light, colchicine undergoes photoisomerization and transforms into structural isomers, called lumicolchicine. After this transformation, colchicine is no longer effective in its mechanistic binding to tubulin, so is not effective as a drug.^[64]

Regulation

It is classified as an extremely hazardous substance in the United States as defined in Section 302 of the U.S. Emergency Planning and Community Right-to-Know Act (42 U.S.C. 11002) and is subject to strict reporting requirements by facilities that produce, store, or use it in significant quantities.^[65]

Formulations and dosing

Trade names for colchicine are Colcrys or Mitigare, which are manufactured as a dark– and light-blue capsule having a dose of 0.6 mg.^[19][66] Colchicine is also prepared as a white, yellow, or purple pill (tablet) having a dose of 0.6 mg.^[66]

Colchicine is typically prescribed to mitigate or prevent the onset of gout, or its continuing symptoms and pain, using a low-dose prescription of 0.6 to 1.2 mg per day, or a high-dose amount of up to 4.8 mg in the first 6 hours of a gout episode.^[6][19] With an oral dose of 0.6 mg, peak blood levels occur within one to two hours.^[40] For treating gout, the initial effects of colchicine occur in a window of 12 to 24 hours, with a peak within 48 to 72 hours.^[19] It has a narrow therapeutic window, requiring monitoring of the subject for potential toxicity.^[19] Colchicine is not a general pain-relief drug, and is not used to treat pain in other disorders.^[19]

Biosynthesis

According to laboratory research, the biosynthesis of colchicine involves the amino acids phenylalanine and tyrosine as precursors. Giving radioactive phenylalanine-2-¹⁴C to C. byzantinum, another plant of the family Colchicaceae, resulted in its incorporation into colchicine.^[67] However, the tropolone ring of colchicine resulted from the expansion of the tyrosine ring. Radioactive feeding experiments of C. autumnale revealed that colchicine can be synthesized biosynthetically from (S)-autumnaline. That biosynthetic pathway occurs primarily through a phenolic coupling reaction involving the intermediate isoandrocymbine. The resulting molecule undergoes O-methylation directed by S-adenosylmethionine. Two oxidation steps followed by the cleavage of the cyclopropane ring lead to the formation of the tropolone ring contained by N-formyldemecolcine. N-formyldemecolcine hydrolyzes then to generate the molecule demecolcine, which also goes through an oxidative demethylation that generates deacetylcolchicine. The molecule of colchicine appears finally after addition of acetyl-coenzyme A to deacetylcolchicine.^[68][69]

 

Purification

Colchicine may be purified from Colchicum autumnale (autumn crocus) or Gloriosa superba (glory lily). Concentrations of colchicine in C. autumnale peak in the summer, and range from 0.1% in the flower to 0.8% in the bulb and seeds.^[25]

Botanical use

Colchicine is widely used in plant breeding by inducing polyploidy in plant cells to produce new or improved varieties, strains, and cultivars.^[12] When used to induce polyploidy in plants, colchicine cream is usually applied to a growth point of the plant, such as an apical tip, shoot, or sucker. Seeds can be presoaked in a colchicine solution before planting. Since chromosome segregation is driven by microtubules, colchicine alters cellular division by inhibiting chromosome segregation during mitosis; half the resulting daughter cells, therefore, contain no chromosomes, while the other half contain double the usual number of chromosomes (i.e., tetraploid instead of diploid), and lead to cell nuclei with double the usual number of chromosomes (i.e., tetraploid instead of diploid).^[12] While this would be fatal in most higher animal cells, in plant cells, it is not only usually well-tolerated, but also frequently results in larger, hardier, faster-growing, and in general more desirable plants than the normally diploid parents. For this reason, this type of genetic manipulation is frequently used in breeding plants commercially.^[12]

When such a tetraploid plant is crossed with a diploid plant, the triploid offspring are usually sterile (unable to produce fertile seeds or spores), although many triploids can be propagated vegetatively. Growers of annual triploid plants not readily propagated vegetatively cannot produce a second-generation crop from the seeds (if any) of the triploid crop and need to buy triploid seed from a supplier each year. Many sterile triploid plants, including some trees and shrubs, are becoming increasingly valued in horticulture and landscaping because they do not become invasive species and do not drop undesirable fruit and seed litter. In certain species, colchicine-induced triploidy has been used to create "seedless" fruit, such as seedless watermelons (Citrullus lanatus). Since most triploids do not produce pollen themselves, such plants usually require cross-pollination with a diploid parent to induce seedless fruit production.

The ability of colchicine to induce polyploidy can be also exploited to render infertile hybrids fertile, for example in breeding triticale (× Triticosecale) from wheat (Triticum spp.) and rye (Secale cereale). Wheat is typically tetraploid and rye diploid, with their triploid hybrid infertile; treatment of triploid triticale with colchicine gives fertile hexaploid triticale.^[70]

Research

COVID-19

Colchicine was researched for potential benefit in treating COVID-19 following hypotheses at the start of the pandemic that it may be an applicable medication. No good evidence of benefit was found.^[71]

References

1. "Colchicine capsule". DailyMed. Retrieved 27 March 2019.
2. "Colchicine Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 27 March 2019.
3. Shekelle PG, Newberry SJ, FitzGerald JD, Motala A, O'Hanlon CE, Tariq A, et al. (January 2017). "Management of Gout: A Systematic Review in Support of an American College of Physicians Clinical Practice Guideline". Annals of Internal Medicine. 166 (1): 37–51. doi:10.7326/M16-0461. PMID 27802478.
4. Schachner LA, Hansen RC (2011). Pediatric Dermatology E-Book. Elsevier Health Sciences. p. 177. ISBN 9780723436652.
5. Hutchison SJ (2009). Pericardial Diseases: Clinical Diagnostic Imaging Atlas with DVD. Elsevier Health Sciences. p. 58. ISBN 9781416052746.
6. . National Prescribing Service, Australia. 14 May 2010. Archived from the original on 30 June 2012. Retrieved 14 May 2010.
7. British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. pp. 1085–1086. ISBN 9780857113382.
8. Dalbeth N, Lauterio TJ, Wolfe HR (October 2014). "Mechanism of action of colchicine in the treatment of gout". Clinical Therapeutics. 36 (10): 1465–1479. doi:10.1016/j.clinthera.2014.07.017. PMID 25151572.
9. Wall WJ (2015). The Search for Human Chromosomes: A History of Discovery. Springer. p. 88. ISBN 9783319263366.
10. "The Top 300 of 2020". ClinCalc. Retrieved 7 October 2022.
11. "Colchicine - Drug Usage Statistics". ClinCalc. Retrieved 7 October 2022.
12. Griffiths AJ, Gelbart WM, Miller JH (1999). "Modern Genetic Analysis: Changes in Chromosome Number". Modern Genetic Analysis. W. H. Freeman, New York.
13. Chen LX, Schumacher HR (October 2008). "Gout: an evidence-based review". Journal of Clinical Rheumatology. 14 (5 Suppl): S55–S62. doi:10.1097/RHU.0b013e3181896921. PMID 18830092. S2CID 6644013.
14. "Colcrys (colchicine, USP) tablets 0.6 mg. Drug Approval Package". US Food and Drug Administration. 17 February 2010. Retrieved 19 August 2018.
15. "Information for Healthcare Professionals: New Safety Information for Colchicine (marketed as Colcrys)". U.S. Food and Drug Administration.
16. Laubscher T, Dumont Z, Regier L, Jensen B (December 2009). "Taking the stress out of managing gout". Canadian Family Physician. 55 (12): 1209–1212. PMC 2793228. PMID 20008601.
17. McKenzie BJ, Wechalekar MD, Johnston RV, Schlesinger N, Buchbinder R (August 2021). "Colchicine for acute gout". The Cochrane Database of Systematic Reviews. 2021 (8): CD006190. doi:10.1002/14651858.CD006190.pub3. PMC 8407279. PMID 34438469.
18. Qaseem A, Harris RP, Forciea MA, Denberg TD, Barry MJ, Boyd C, et al. (January 2017). "Management of Acute and Recurrent Gout: A Clinical Practice Guideline From the American College of Physicians". Annals of Internal Medicine. 166 (1): 58–68. doi:10.7326/M16-0570. PMID 27802508.
19. "Colchicine". Drugs.com. 1 January 2017. Retrieved 19 August 2018.
20. McKenzie BJ, Wechalekar MD, Johnston RV, Schlesinger N, Buchbinder R (August 2021). "Colchicine for acute gout". The Cochrane Database of Systematic Reviews. 2021 (8): CD006190. doi:10.1002/14651858.CD006190.pub3. PMC 8407279. PMID 34438469.
21. Nelson K, Fuster V, Ridker P, et al. (2023 Aug) "Low-Dose Colchicine for Secondary Prevention of Coronary Artery Disease". J Am Coll Cardiol. 82 (7) 648–660. https://doi.org/10.1016/j.jacc.2023.05.055
22. Cocco G, Chu DC, Pandolfi S (December 2010). "Colchicine in clinical medicine. A guide for internists". European Journal of Internal Medicine. 21 (6): 503–508. doi:10.1016/j.ejim.2010.09.010. PMID 21111934.
23. Puéchal X, Terrier B, Mouthon L, Costedoat-Chalumeau N, Guillevin L, Le Jeunne C (March 2014). "Relapsing polychondritis". Joint Bone Spine. 81 (2): 118–124. doi:10.1016/j.jbspin.2014.01.001. PMID 24556284. S2CID 205754989.
24. Alabed S, Cabello JB, Irving GJ, Qintar M, Burls A, Nelson L (August 2014). "Colchicine for pericarditis". The Cochrane Database of Systematic Reviews. 2014 (8): CD010652. doi:10.1002/14651858.CD010652.pub2. PMC 10645160. PMID 25164988.
25. Hoffman RS, Nelson LS, Goldfrank LR, Howland MA, Lewin NA, Smith SW (11 April 2019). Goldfrank's toxicologic emergencies (Eleventh ed.). New York. ISBN 978-1-259-85961-8. OCLC 1020416505.{{cite book}}: CS1 maint: location missing publisher (link)
26. Portincasa P (2016). "Colchicine, Biologic Agents and More for the Treatment of Familial Mediterranean Fever. The Old, the New, and the Rare". Current Medicinal Chemistry. 23 (1): 60–86. doi:10.2174/0929867323666151117121706. PMID 26572612.
27. Lennerz C, Barman M, Tantawy M, Sopher M, Whittaker P (December 2017). "Colchicine for primary prevention of atrial fibrillation after open-heart surgery: Systematic review and meta-analysis" (PDF). International Journal of Cardiology. 249: 127–137. doi:10.1016/j.ijcard.2017.08.039. PMID 28918897.
28. Malik J, Javed N, Ishaq U, Khan U, Laique T (May 2020). "Is There a Role for Colchicine in Acute Coronary Syndromes? A Literature Review". Cureus. 12 (5): e8166. doi:10.7759/cureus.8166. PMC 7296886. PMID 32550081.
29. Imazio M, Andreis A, Brucato A, Adler Y, De Ferrari GM (October 2020). "Colchicine for acute and chronic coronary syndromes". Heart. 106 (20): 1555–1560. doi:10.1136/heartjnl-2020-317108. PMID 32611559. S2CID 220305546.
30. Nidorf SM, Fiolet AT, Mosterd A, Eikelboom JW, Schut A, Opstal TS, et al. (November 2020). "Colchicine in Patients with Chronic Coronary Disease". The New England Journal of Medicine. 383 (19): 1838–1847. doi:10.1056/NEJMoa2021372. PMID 32865380.
31. "CDC - The Emergency Response Safety and Health Database: Biotoxin: Cochicine". Centers for Disease Control and Prevention, US Department of Health and Human Services. Retrieved 31 December 2015.
32. Finkelstein Y, Aks SE, Hutson JR, Juurlink DN, Nguyen P, Dubnov-Raz G, et al. (June 2010). "Colchicine poisoning: the dark side of an ancient drug". Clinical Toxicology. 48 (5): 407–414. doi:10.3109/15563650.2010.495348. PMID 20586571. S2CID 33905426.
33. Doogue M (2014). "Colchicine – extremely toxic in overdose" (PDF). Christchurch and Canterbury District Health Board, New Zealand. Retrieved 23 August 2018.
34. Jankowski W, Kurek J, Barczyński P, Hoffmann M (April 2017). "Quantum-chemical, NMR, FT IR, and ESI MS studies of complexes of colchicine with Zn(II)". Journal of Molecular Modeling. 23 (4): 127. doi:10.1007/s00894-017-3306-z. PMC 5393104. PMID 28321655.
35. Schwier NC, Cornelio CK, Boylan PM (April 2022). "A systematic review of the drug-drug interaction between statins and colchicine: Patient characteristics, etiologies, and clinical management strategies". Pharmacotherapy. 42 (4): 320–333. doi:10.1002/phar.2674. PMID 35175631. S2CID 246903117.
36. Niel E, Scherrmann JM (December 2006). "Colchicine today". Joint Bone Spine. 73 (6): 672–8. doi:10.1016/j.jbspin.2006.03.006. PMID 17067838.
37. Drion N, Lemaire M, Lefauconnier JM, Scherrmann JM (October 1996). "Role of P-glycoprotein in the blood-brain transport of colchicine and vinblastine". J Neurochem. 67 (4): 1688–93. doi:10.1046/j.1471-4159.1996.67041688.x. PMID 8858954. S2CID 38446612.
38. Cisternino S, Rousselle C, Debray M, Scherrmann JM (October 2003). "In vivo saturation of the transport of vinblastine and colchicine by P-glycoprotein at the rat blood-brain barrier". Pharm Res. 20 (10): 1607–11. doi:10.1023/a:1026187301648. PMID 14620515. S2CID 10193442.
39. Graham W, Roberts JB (March 1953). "Intravenous colchicine in the management of gouty arthritis". Annals of the Rheumatic Diseases. 12 (1): 16–19. doi:10.1136/ard.12.1.16. PMC 1030428. PMID 13031443.
40. "Colcrys (colchicine). Summary review for regulatory action" (PDF). Center for Drug Evaluation and Research, US Food and Drug Administration. 30 July 2009. Retrieved 19 August 2018.
41. Hartung EF (September 1954). "History of the use of colchicum and related medicaments in gout; with suggestions for further research". Annals of the Rheumatic Diseases. 13 (3): 190–200. doi:10.1136/ard.13.3.190. PMC 1006735. PMID 13198053. (free BMJ registration required)
42. Ebadi MS (2007). Pharmacodynamic basis of herbal medicine. CRC Press. ISBN 978-0-8493-7050-2.
43. Pelletier PS, Caventou JB (1820). "Examen chimique des plusieurs végétaux de la famille des colchicées, et du principe actif qu'ils renferment. [Cévadille (veratrum sabadilla); hellébore blanc (veratrum album); colchique commun (colchicum autumnale)]" [Chemical examination of several plants of the meadow saffron family, and of the active principle that they contain.]. Annales de Chimie et de Physique. 14: 69–81.
44. Geiger, Ph. L. (1833) "Ueber einige neue giftige organische Alkalien" (On some new poisonous organic alkalis) Annalen der Pharmacie, 7 (3) : 269-280; colchicine is discussed on pages 274-276.
45. Dewar MJ (3 February 1945). "Structure of colchicine". Letters to Editor. Nature. 155 (3927): 141–142. Bibcode:1945Natur.155..141D. doi:10.1038/155141d0. S2CID 4074312. Dewar did not prove the structure of colchicine; he merely suggested that it contained two seven-membered rings. Colchicine's structure was determined by X-ray crystallography in 1952 King MV, de Vries JL, Pepinsky R (July 1952). "An x-ray diffraction determination of the chemical structure of colchicine". Acta Crystallographica. 5 (4): 437–440. doi:10.1107/S0365110X52001313. Its total synthesis was first accomplished in 1959 Eschenmoser A (1959). "Synthese des Colchicins". Angewandte Chemie. 71 (20): 637–640. Bibcode:1959AngCh..71..637S. doi:10.1002/ange.19590712002.
46. Albert Eschenmoser The Franklin Institute. fi.edu. Accessed 24 Sep 2023.
47. "FDA Unapproved Drugs Initiative". Food and Drug Administration.
48. Langreth R, Koons C (6 October 2015). "2,000% Drug Price Surge Is a Side Effect of FDA Safety Program". Bloomberg.com. Bloomberg. Retrieved 27 October 2015.
49. "FDA Approves Colchicine With Drug Interaction and Dose Warnings". July 2009.
50. "Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations". fda.gov.
51. "Questions and Answers for Patients and Healthcare Providers Regarding Single-ingredient Oral Colchicine Products". fda.gov.
52. . medpagetoday.com. 3 August 2009. Archived from the original on 5 August 2009. Retrieved 3 August 2009.
53. Cerquaglia C, Diaco M, Nucera G, La Regina M, Montalto M, Manna R (February 2005). . Current Drug Targets. Inflammation and Allergy. 4 (1): 117–124. doi:10.2174/1568010053622984. PMID 15720245. Archived from the original on 11 December 2008. Retrieved 6 July 2019.
54. Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW (April 2010). "High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study". Arthritis and Rheumatism. 62 (4): 1060–1068. doi:10.1002/art.27327. PMID 20131255. S2CID 205424044.
55. Karst KR (21 October 2009). "California Court Denies Preliminary Injunction in Lanham Act Case Concerning Unapproved Colchicine Drugs".
56. Meyer H (29 December 2009). "The High Price of FDA Approval". The Philadelphia Inquirer – via Kaiser Health News.
57. Colcrys vs. Unapproved Colchicine Statement from URL Pharma
58. "About Colcrys". Colcrys. URL Pharma. Retrieved 11 September 2011.
59. Kesselheim AS, Solomon DH (June 2010). "Incentives for drug development--the curious case of colchicine". The New England Journal of Medicine. 362 (22): 2045–2047. doi:10.1056/NEJMp1003126. PMID 20393164.
60. "FDA orders halt to marketing of unapproved single-ingredient oral colchicine". Food and Drug Administration. 30 September 2010.
61. "Generic Colcrys Availability". drugs.com.
62. "Colchicine". PubChem. National Center for Biotechnology Information. Retrieved 7 November 2021.
63. Sapra S, Bhalla Y, Sharma S, Singh G, Nepali K, Budhiraja A, Dhar KL (13 May 2012). "Colchicine and its various physicochemical and biological aspects". Medicinal Chemical Research. 22 (2): 531. doi:10.1007/s00044-012-0077-z. S2CID 13211030. Retrieved 7 November 2021.
64. Sagorin C, Ertel NH, Wallace SL (March 1972). "Photoisomerization of colchicine. Loss of significant antimitotic activity in human lymphocytes". Arthritis and Rheumatism. 15 (2): 213–217. doi:10.1002/art.1780150213. PMID 5027606.
65. "40 CFR Appendix A to Part 355, The List of Extremely Hazardous Substances and Their Threshold Planning Quantities". LII / Legal Information Institute. Retrieved 11 March 2018.
66. "Colchicine images". Drugs.com. 6 August 2018. Retrieved 21 August 2018.
67. Leete E (1963). "The biosynthesis of the alkaloids of Colchicum: The incorporation of phenylalaline-2-C14 into colchicine and demecolcine". J. Am. Chem. Soc. 85 (22): 3666–3669. doi:10.1021/ja00905a030.
68. Herbert RB (February 2001). "The biosynthesis of plant alkaloids and nitrogenous microbial metabolites". Natural Product Reports. 18 (1): 50–65. doi:10.1039/A809393H. PMID 11245400.
69. Dewick PM (2009). Medicinal natural products: A biosynthetic approach. Wiley. pp. 360–362.
70. Dermen H, Emsweller SL (1961). "The use of colchicine in plant breeding". archive.org. Retrieved 26 April 2016.
71. Long B, Chavez S, Carius BM, Brady WJ, Liang SY, Koyfman A, Gottlieb M (June 2022). "Clinical update on COVID-19 for the emergency and critical care clinician: Medical management". Am J Emerg Med (Review). 56: 158–170. doi:10.1016/j.ajem.2022.03.036. PMC 8956349. PMID 35397357.

Further reading

• Dowd MJ (30 April 1998). . Virginia Commonwealth University. Archived from the original on 10 June 2010.

External links

 

Wikimedia Commons has media related to Colchicine.

• "Colchicine". Drug Information Portal. U.S. National Library of Medicine.
• "Colchicine : Biotoxin". Emergency Response Safety and Health Database. 8 November 2017.